| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Dendreon Corporation |
| 3005 First Avenue, Seattle, WA 98121 * (206) 256-4545 |
| Business Description | The company discovers and develops immunologically based therapeutic products for the treatment of cancer. |
| Offering Information Company has | |||
| Trading As | DNDN (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 3/8/00 |
| Domestic Shares Offered | 4,500,000 | Offer Date | 6/15/00 |
| Foreign Shares Offered | 0 | Filing Range | $12.00 - $14.00 |
| Company Shares | 4,500,000 | Offer Price | $10.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.700 |
| Gross Proceeds | $45,000,000 | Selling | $0.400 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 20,760,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Prudential Vector Healthcare | Lead Manager | (800) 546-1231 |
| Pacific Growth Equities | Co-manager | (415) 274-6800 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 0.793 | 1.849 | 3.519 | - | - |
| Income from Oper. | - | - | -7.391 | -9.067 | -12.774 | - | - |
| Net Income | - | - | -7.163 | -9.349 | -12.679 | - | - |
| E.P.S | - | - | -23.510 | -16.340 | -15.080 | - | - |
| Revenue Growth (%) | - | - | 133.17 | 90.319 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -12.10 | - | - | ||||
| Cash Flow - Inv. | -4.53 | - | - | ||||
| Cash Flow - Fin. | 16.84 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 17.38 | Current Assets | 15.20 | Current Ratio | 2.89 |
| Total Liab. | 11.02 | Current Liab. | 5.26 | Debt Ratio | 63.44% |
| Total Equity | 6.35 | Working Cap. | 9.94 | Debt to Equity Ratio | 1.74 |
| Cash | 7.09 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund clinical trials, research, preclinical and commercialization activities for our therapeutic vaccine products, to increase our dentritic cell processing and antigen manufacturing capability and for general corporate purposes including working capital. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Skadden, Arps, Slate, Meagher & Flom |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Entities affiliated with Healthcare Ventures LLC | 24.00 | |
| Vulcan Ventures Incorporated | 21.80 | |
| Entities affiliated with Sanderling Ventures | 7.70 | |
| Kummell Investments Limited | 7.00 | |
| Europort, Gibralter (via London) New York Life Insurance Co. | 5.50 | |
| Note: represents ownership of 5% or more prior to the offering. | ||